Preliminary Evaluation of Over 100 Patients Treated with Cancer Blood Vessel Targeting Immunotherapy Reveals Gene Association with Clinical Response
Clinical Stage Immunotherapy Company Creates System of Selecting Patients for Optimized Outcome under President Donald Trump’s Right to Try Law
Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor”
Clinical Stage Immuno-Oncology Company Recruits Pioneer of Innate Immunity to Scientific Advisory Board
Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board.
Company discusses the clinical progress of the ValloVax Therapeutic Vaccine at the CHIPSA Hospital
Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareholders of the Company, providing a comprehensive update on the clinical progress of the ValloVax immune therapy:
Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign
Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Product ValloVax
Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 Million in capital to the Company.
Batu Biologics Recruits Diagnostics Expert to Oversee Precision-Medicine Company Arm
Vijay Mahant, PhD, will lead efforts in the development of gene-guided precision medicine related to the ValloVax immune therapy
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Vijay Mahant, PhD, to its Scientific Advisory Board.
Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences
Batu Biologics, an immuno-oncology company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.
Founder of Batu Biologics Expands Involvement as Chief Scientific Officer
Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.
Vice Chairman of Immunology at The Scripps Research Institute to Assist with ValloVax™ Clinical Development
Argyrios Theofilopoulos, MD, Joins Batu’s Scientific Advisory Board
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Argyrios Theofilopoulos, MD of The Scripps Research Institute to its scientific advisory board.
Batu Biologics Continues Fight in War Against Lung Cancer
Closure of $1 million seed round to support development of anti-angiogenic immune therapy, ValloVax™
Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.